Area of research
Hematology · Genetics
Research interest
Research focused on Myeloid leukemia and RUNX1, with related work in Core binding factor, Leukemia, Oncology. Notable publications include 'Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia', 'A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia', and 'Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis'.
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome
Risk Stratification of Patients with <i>RUNX1-</i>mutated Acute Myeloid Leukemia
Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
The clinical mutatome of core binding factor leukemia
Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia
Clinical presentation and differential splicing of <i>SRSF2, U2AF1</i> and <i>SF3B1</i> mutations in patients with Acute Myeloid Leukaemia
Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia
ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation
Acute myeloid leukemia with del(9q) is characterized by frequent mutations of <i>NPM1</i>, <i>DNMT3A, WT1</i> and low expression of <i>TLE4</i>
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia
Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis
Long-term follow-up of cytogenetically normal CEBPA-mutated AML
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia
Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity
Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis